Home › Therapeutic areas › Immunology › Chronic Urticaria
Chronic Urticaria (8 companies)
Companies with an active program in Chronic Urticaria.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 1 | Phase 3 | $2.63B | 8 |
| CLDX | Celldex Therapeutics | DermatologyImmunology+1 | 4 | Phase 3 | $2.35B | 9 |
| CUE | Cue Biopharma | ImmunologyOncology | 1 | Phase 2 | $136M | 6 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+1 | 1 | Approved | $320M | 7 |
| EVMN | Evommune | DermatologyImmunology+1 | 1 | Phase 2 | $241M | 6 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.67B | 13 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $5.4M | 7 |
| SEPN | Septerna | ImmunologyMetabolic+1 Rare | 2 | Phase 1 | $2.28B | 5 |
No companies match.